Drug Trial Radar · NCT06843447
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
605
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Mar 27, 2029
Study completion Feb 7, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
Conditions
- Ovarian Cancer Recurrent
Interventions
Raludotatug DeruxtecanBiological
IV infusion on Day 1 of every 3-week cycle.
CarboplatinDrug
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
PaclitaxelDrug
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
BevacizumabBiological
IV infusion on Day 1 of every 3-week cycle.
Rescue MedicationDrug
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.
PembrolizumabBiological
IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.
GemcitabineDrug
IV injection on days 1 and 8 of each 3-week Cycle
Pegylated liposomal doxorubicinDrug
IV injection administered on Day 1 of each 4-week cycle
MK-2010Drug
IV infusion on Day 1 of every 3-week cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)Time frame: Up to 21 days
- Part 1: Number of Participants with One or More Adverse Events (AEs)Time frame: Up to approximately 3 years
- Part 1: Number of Participants who Discontinue Study Intervention Due to an AETime frame: Up to approximately 3 years
- Part 2: Objective Response Rate (ORR)Time frame: Up to approximately 3 years
- Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2Time frame: Up to approximately 3 years
Locations
42 sites in 9 countries. Site status is shown where the registry gives one.
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
New Haven, Connecticut · Recruiting
The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
Louisville, Kentucky · Recruiting
TRIALS 365 ( Site 0020)
Shreveport, Louisiana · Recruiting
Dana-Farber Cancer Institute ( Site 0015)
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 0003)
New York, New York · Recruiting
OU Health University of Oklahoma Medical Center ( Site 7000)
Oklahoma City, Oklahoma · Recruiting
Texas Oncology - DFW ( Site 8000)
Fort Worth, Texas · Recruiting
Houston Methodist Hospital ( Site 0010)
Houston, Texas · Completed
START Mountain Region ( Site 0008)
West Valley City, Utah · Recruiting
University of Virginia Health System ( Site 0011)
Charlottesville, Virginia · Recruiting
Western Health-Sunshine & Footscray Hospitals ( Site 1002)
St Albans, Victoria, Australia · Recruiting
Princess Margaret Cancer Centre ( Site 0101)
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier de l'Université de Montréal ( Site 0102)
Montreal, Quebec, Canada · Recruiting
McGill University Health Centre ( Site 0100)
Montreal, Quebec, Canada · Recruiting
Rambam Health Care Campus ( Site 0202)
Haifa, Israel · Recruiting
Shaare Zedek Medical Center ( Site 0201)
Jerusalem, Israel · Recruiting
Rabin Medical Center ( Site 0203)
Petah Tikva, Israel · Recruiting
Sheba Medical Center ( Site 0200)
Ramat Gan, Israel · Recruiting
Seoul National University Hospital ( Site 2000)
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System ( Site 2002)
Seoul, South Korea · Recruiting
Asan Medical Center ( Site 2003)
Seoul, South Korea · Recruiting
Samsung Medical Center ( Site 2001)
Seoul, South Korea · Recruiting
National Cancer Center ( Site 2004)
Goyang-si, Kyonggi-do, South Korea · Recruiting
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
Barcelona, Spain · Recruiting
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre ( Site 0304)
Madrid, Spain · Recruiting
Hospital Universitario Virgen de la Victoria ( Site 0306)
Málaga, Spain · Recruiting
Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
Majadhonda, Madrid, Spain · Recruiting
Clinica Universidad de Navarra ( Site 0301)
Madrid, Madrid, Comunidad de, Spain · Recruiting
Hospital General Universitario de Valencia ( Site 0305)
Valencia, Valenciana, Comunitat, Spain · Recruiting
HOCH Health Ostschweiz ( Site 0801)
Sankt Gallen, Switzerland · Recruiting
University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
Basel, Canton of Basel-City, Switzerland · Recruiting
CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
Lausanne, Canton of Vaud, Switzerland · Recruiting
National Taiwan University Hospital ( Site 3001)
Taipei, Taiwan · Recruiting
Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
Taoyuan, Taiwan · Recruiting
The Christie NHS Foundation Trust ( Site 0405)
Manchester, United Kingdom · Recruiting
University Hospitals Sussex NHS Foundation Trust ( Site 0404)
Brighton, East Sussex, United Kingdom · Recruiting
Royal Marsden Hospital ( Site 0402)
Fulham, England, United Kingdom · Recruiting
The Royal Marsden NHS Foundation Trust. ( Site 0403)
Sutton, England, United Kingdom · Recruiting
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.